Print this page


Dr. Doug Arnold
is a neurologist with special expertise in advanced brain imaging acquisition and analysis techniques, particularly as they relate to understanding the evolution of multiple sclerosis (MS) and other neurodegenerative diseases. Dr. Arnold’s research is focused on combining advanced image processing techniques with conventional and non-conventional magnetic resonance imaging (MRI) acquisition techniques (such as magnetization transfer imaging, magnetic resonance spectroscopy and functional MRI) to better understand the effects of MS on the brain. He also uses these techniques to better understand the effects of new therapies for MS.

Jonathan D. Glass received his undergraduate degree from Middlebury College (Vermont) and his MD from the University of Vermont.  He trained in Neurology and Neuropathology at Johns Hopkins Hospital in Baltimore, where he was a faculty member until being recruited to Emory University in 1996. He is widely known for his research on the pathogenesis and prevention of nerve degeneration in neurological diseases, and for his work in human and experimental neuropathology.  His laboratory focuses on the study of ALS and other neurodegenerative diseases using animal models, cell cultures, and human tissues to investigate the causes and potential cures for ALS.  Dr. Glass is also Director of the Emory ALS Center, which has grown to be one of the largest clinical centers in the Southeastern United States.  He is the co-Chair of the Northeast ALS Consortium (NEALS), an organization dedicated to advancing clinical research for ALS patients and their families.  Dr. Glass is an active clinician who has been cited each year since 2001 as one of  "America's Top Doctors" (Castle Connelly) and since 2005 as one of "Atlanta's Top Doctors" (Atlanta Magazine).  He is also a teacher and mentor to young physicians and served as the director of Emory's Neurology residency training program from 2001-2006.

Dr. Michael Hill is a Professor for the Departments of Clinical Neurosciences, Community Health Sciences, Medicine and Radiology at the University of Calgary.  He is also Director of the Stroke Unit for the Calgary Stroke Program, Alberta Health Services.

Dr. Hill completed undergraduate training at McGill University in biochemistry and went on to the University of Ottawa medical school. He trained in internal medicine at the University of Ottawa and received his FRCPC (Internal Medicine) in 1997. Subsequently, he completed a neurology residency at the University of Toronto and received his FRCPC (Neurology) in 1999. Dr. Hill moved to Calgary to undertake a stroke fellowship and clinical epidemiology training at the University of Calgary and was appointed to faculty in 2001.  He then completed his MSc thesis in 2003, and is currently Director of the Stroke Unit at the Foothills Medical Centre, Calgary Health Region.

Dr. Hill’s research interests include stroke thrombolysis, stroke epidemiology, and surveillance and clinical trials.  He is funded by the Canadian Institutes for Health Research (CIHR) and holds the Heart & Stroke Foundation of Alberta/NWT/Nunavut professorship in Stroke Research. He holds and has held operating and clinical trials grants from the CIHR, Heart & Stroke Foundation of Alberta/NWT/Nunavut and from various industry partners as well as  NIH (NINDS). Dr. Hill has also received a number of awards, including the Barnett, The Pessin Award and the ARP merit award and the Performance Recognition award for his role in research and his outstanding publication record.

Dr. Keene is the Senior Medical Advisor at CERB. In addition, he is the Head of the Drug Safety Unit and Acting Chief of the Clinical Trials Division.  

Dr Keene obtained a   BSc.(MED) and MD from the University of Saskatchewan. After completing medical school, he did postgraduate medical training in pediatrics at the Hospital for Sick Children in Toronto and in neurology at the Montreal Neurological Institute. He is a fellow of the Royal College of Physicians and Surgeons of Canada (speciality certification in pediatrics and neurology).   He has an MA (Public Administration/Public Policy) from Carleton University, and a graduate certification in Academic Excellence in Epidemiology from the School of Public Health, University of Michigan. He has published numerous peer-reviewed articles and book chapters on pediatric neurological disease, neuro-oncology, epidemiology and health policy. 

Dr. Roger M Lane graduated the Bristol University Medical School, UK in1984. He completed his Masters in Public Health, Columbia University, New York in 1998. After 5 years in pediatrics/general medicine, Dr. Lane entered Roche, UK in early oncology clinical development in 1989. In continued in global medical with Pfizer NYC (1992-2001), leading global clinical development and medical support for the commercialization of Zoloft. At Novartis (2001-10) as Disease Area Section Head for Dementia where he developed Exelon capsules for Parkinson’s disease dementia and the Exelon transdermal patch for Alzheimer’s. In 2010 Dr. Lane joined BMS as Development and Medical Affairs Lead for a series of triple monoamine reuptake inhibitors. At Ionis Pharmaceuticals, Inc. from 2014 in early clinical development in neurology, including leading the Phase 1-2a trials for antisense oligonucleotides targeting the Huntingtin and tau gene expression. Authored over 90 peer reviewed publications, including 28 review articles, and inventor of 3 patents.

Dr. Tim M Miller is a clinical & basic science trained neurologist with neuromuscular/rare/orphan disease fellowships and therapeutics development expertise in Neurology, Cardiology and Rare Disease applications.

Dr. Marc Rivière joined TVM Life Science Management in 2013 after twenty years of international drug development and ten years of medical and public health practice.

Marc has successfully built and managed clinical programs in multiple clinical indications encompassing all aspects of drug development from pre-clinical development to post marketing surveillance.  As General Partner and Chief Medical Officer, he focuses on evaluation of deal opportunities and investment management for therapeutics.

Prior to joining TVM, Marc was Vice-President, Axcan/Aptalis Pharma Inc., in charge of Clinical Development, Medical Affairs and Pharmacovigilance, Senior Vice President, Clinical Development at Caprion Pharmaceuticals, Chief Medical Officer for Bioniche Life Sciences Inc., Managing Director of Xenon Genetics Inc., Vice President of Clinical Affairs, Aeterna Laboratories and Executive Vice President and Regional Director, Quintiles Inc. 

Marc received his Tropical Disease Medicine Certification from Université Bordeaux II, France and Medicine Doctorate from Université Paul Sabatier, Toulouse, France.

Dr. Warren Wasiewski is the Chief Medical Officer and Vice President of Clinical Research and Development at Bioblast Pharm, a small biotech who is developing treatments for orphan diseases.  He is  board-certified Pediatric Neurologist with 23 years of clinical experience in Pediatric Neurology and 16 years of experience in the pharmaceutical industry.  Dr. Wasiewski was Chief Medical Officer and Executive Vice President of Clinical Development for Neurotrope BioScience, leading its Alzheimer’s disease program as well as two orphan indications. Prior to this, he was Vice President of Clinical Development for Neurology at Alexion Pharmaceuticals were he also worked in the orphan disease space. Dr Wasiewski a Senior Medical Director for AstraZeneca in Neurology where he led the global stroke program.
Dr. Wasiewski’s clinical career includes both academic and private practice as an Associate Professor of Pediatrics at Penn State Children’s Hospital and Chair of Pediatrics at Lancaster General Hospital. His pharmaceutical experience has spanned all aspects of drug development, including all 4 phases of clinical development, establishing global regulatory strategy, assessing business development opportunities and mergers, and raising capital to support clinical programs. Dr. Wasiewski has extensive clinical trial design experience and expertise, particularly in study design for orphan indications.
Dr. Wasiewski has a BA from Rutgers College, an MS from State University of New York Downstate Medical Center in Biochemistry, and an MD from State University of New York, Buffalo.